← Every company
Arrowhead Pharmaceuticals Inc Patents
What Arrowhead Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ARWR on carbonthat →Filings on file
53
Granted
3
Still pending
50
Filed under
2 names
53 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of UseA61K 45/06, C12N 15/1137, A61K 47/543, A61P 25/28, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3233, C12N2310/332, C12N2310/333, C12N2310/334, C12N2310/335, C12N2310/336, C12N2310/351, C12N2310/3515, C12Y 115/01001, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2026-02-02Christine Esau | pending |
| RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of UseA61K 47/6807, C12N 15/113, A61K 47/542, A61K 47/549, A61K 47/6849, A61P 25/28, C07K 16/2881, C12N2310/11, C12N2310/14, C12N2310/312, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2026-01-14Phillip Lazzara | pending |
| ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOFA61K 47/6807, C07K 16/2881, A61K 47/6849, A61K2039/505, C07K2317/24, C07K2317/55, C07K2317/92, C12N 15/1138, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/332, C12N2310/3513, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-12-22Agnieszka Glebocka | pending |
| RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of UseC12N 15/1137, A61K 47/549, A61P 1/16, A61K 31/713, A61K 45/06, A61K2300/00, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/323, C12N2310/331, C12N2310/343, C12N2310/346, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/31, C12Y 101/00Filed as Arrowhead Pharmaceuticals, Inc.2025-12-17Zhen LI | pending |
| RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of UseC12N 15/113, A61P 1/16, A61P 3/04, A61P 3/06, A61P 3/10, A61K 31/713, C12N2310/14, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/351, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-12-15Michelle Ngai | pending |
| Metabolically Stabilized Carbohydrate Targeting Ligands For Oligonucleotide ConjugatesC12N 15/111, C12N 15/113, A61K 47/549, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Arrowhead Pharmaceuticals, Inc.2025-11-26Agnieszka Glebocka | pending |
| Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use ThereofC12N 15/113, A61K 47/549, C12N 15/1137, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2310/51Filed as Arrowhead Pharmaceuticals, Inc.2025-11-26Agnieszka Glebocka | pending |
| RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of UseC12N 15/113, C12N 15/1138, A61K 47/545, A61P 11/00, A61K 9/0073, A61K 31/713, A61K 45/06, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/32, C12N2310/317, C12N2310/332Filed as Arrowhead Pharmaceuticals, Inc.2025-11-19Anthony Nicholas | pending |
| RNAI AGENTS FOR DUAL INHIBITION OF EXPRESSION OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) AND INTERLEUKIN 33 (IL33), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-11-03TINGTING YUAN | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF INTERLEUKIN 33 (IL33), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-11-03TINGTING YUAN | pending |
| RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of UseC12N 15/111, C12N 15/113, C12N 15/1137, C07F 9/24, C07H 1/00, C07H 19/10, C07H 21/00, C07H 23/00, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/332, C12N2310/343, C12N2310/344, C12N2310/346, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/35, C12Y 207/1103Filed as Arrowhead Pharmaceuticals, Inc.2025-10-10Michelle Ngai | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF ATAXIN-2 (ATXN2), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-09-16Ji Young SUK | pending |
| RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of UseA61P 1/16, C12N 15/1137, A61P 37/06, A61P 3/06, A61K 9/0019, A61K 47/02, C12N2310/11, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12N2320/35, C12Y 107/00Filed as Arrowhead Pharmaceuticals, Inc.2025-09-15Jonathan Van Dyke | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF SYNUCLEIN ALPHA (SNCA), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-09-15PALOMA MARTINEZ-REDONDO | pending |
| RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of UseFiled as Arrowhead Pharmaceuticals, Inc.2025-09-12Christine Esau | pending |
| 5'-CYCLO-PHOSPHONATE MODIFIED NUCLEOTIDESC07H 19/067, C07H 19/10, A61P 43/00, A61P 1/16, A61P 31/20, C07H 1/00, C07H 19/06, C07H 19/16, C07H 19/167, C07H 19/207, C07H 21/00, C07H 21/02, C12N 15/113, C12N2310/14, C12N2310/31, C12N2310/312, C12N2310/323, C12N2310/3231, C12N2310/3233, C12N2310/3519Filed as Arrowhead Pharmaceuticals, Inc.2025-08-27Zhen Li | pending |
| RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of UseC12N 15/1137, A61P 3/06, A61K 47/02, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/351, C12Y 304/21061, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-08-27Zhao Xu | pending |
| RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of UseC12N 15/1136, A61P 11/06, A61K 31/7115, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/351, C12N2320/32, C12N2320/35, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-08-14Casi Schienebeck | pending |
| Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of UseF23R 3/286, A61P 31/14, C12N 15/1131, C12N2310/14, C12N2310/321, C12N2310/351, F23C2900/9901, F23R 3/002, F23R 3/283, F23R 3/50, F23R2900/00002Filed as Arrowhead Pharmaceuticals, Inc.2025-07-31Casi Schienebeck | pending |
| BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESISFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-07-31Karsten KELLER | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF YELLOW FEVER VIRUS (YFV) VIRAL GENOME EXPRESSION, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-07-30KEIVAN ZANDI | pending |
| LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTSFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-07-28GEORGE NACLERIO III | pending |
| GLUCAGON-LIKE PEPTIDE-1 (GLP1) RECEPTOR LIGANDS FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CARDIOMYOCYTESFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-07-28GEORGE NACLERIO III | pending |
| CARDIOMYOCYTE DELIVERY PLATFORMS AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-07-28GEORGE NACLERIO III | pending |
| RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of UseC12N 15/113, A61K 47/545, A61P 11/12, A61P 11/06, A61P 35/00, A61K 31/713, A61K 45/06, A61K2300/00, C07H 21/02, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/351, C12N2310/3513, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Arrowhead Pharmaceuticals, Inc.2025-07-21Erik W. Bush | pending |
| RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of UseA61P 31/16, C12N 15/1131, A61K 47/545, A61K 31/713, C12N2310/14, C12N2310/313, C12N2310/314, C12N2310/315, C12N2310/321, C12N2310/351, C12N2310/322, C12N2310/3533, C12N2310/3521Filed as Arrowhead Pharmaceuticals, Inc.2025-07-11Erik W. Bush | pending |
| LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUEA61K 47/543, C12N 15/1138, A61K 31/713, C12N 15/111, C12N 15/113, C12N 15/1136, C12N 15/1137, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/333, C12N2310/343, C12N2310/344, C12N2310/3513, C12N2310/3515, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Arrowhead Pharmaceuticals, Inc.2025-07-03Mark Majewski | pending |
| RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of UseC12N 15/113, C12N 15/1137, A61P 13/12, A61K 31/7088, C12N 15/63, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/32, C12Y 304/21Filed as Arrowhead Pharmaceuticals, Inc.2025-06-26Xiaokai Li | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF HUNTINGTIN (HTT), COMPOSITIONS THEREOF, AND METHODS OF USEA61K 47/6807, C12N 15/113, A61K 47/6843, C07K 16/18, C07K2317/55, C12N2310/11, C12N2310/14, C12N2310/31, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/351, C12N2310/3513, C12N2310/3515, C12N2310/3521, C12N2310/3533Filed as ARROWHEAD PHARMACEUTICALS, INC.2025-06-20Christine ESAU | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF HUNTINGTIN (HTT), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-06-20CHRISTINE ESAU | pending |
| RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)C12N 15/113, A61P 9/10, A61P 1/18, A61P 3/04, A61K 9/0019, A61K 31/7088, A61K 31/7125, C07H 3/02, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/3233, C12N2310/332, C12N2310/343, C12N2310/346, C12N2310/351, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-06-18Zhen Li | pending |
| RNAi Agents for Dual Inhibition of Expression of Thymic Stromal Lymphopoietin (TSLP) and Interleukin 33 (IL33), Compositions Thereof, and Methods of UseFiled as Arrowhead Pharmaceuticals, Inc.2025-05-06Tingting Yuan | pending |
| RNAi Agents for Inhibiting Expression of Interleukin 33 (IL33), Compositions Thereof, and Methods of UseFiled as Arrowhead Pharmaceuticals, Inc.2025-05-06Tingting Yuan | pending |
| RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of UseFiled as Arrowhead Pharmaceuticals, Inc.2025-05-05Christine Esau | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF MYOCILIN (MYOC), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-04-25XIAOKAI LI | pending |
| RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UseA61K 31/712, C12N 15/113, A61K 47/549, A61P 43/00, A61P 37/06, A61K 31/713, A61K 47/02, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Arrowhead Pharmaceuticals, Inc.2025-04-24Jeffrey Carlson | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF DM1 PROTEIN KINASE (DMPK) COMPOSITIONS THEREOF, AND METHODS OF USEC12N 15/1137, A61K 47/64, A61K 47/60, A61K 47/554, A61P 21/00, A61K 31/712, A61K 31/7125, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/332, C12N2310/3513, C12N2310/3515, C12N2320/32Filed as ARROWHEAD PHARMACEUTICALS, INC.2025-04-11Jonathan VAN DYKE | pending |
| RNAi Agents for Inhibiting Expression of Synuclein Alpha (SNCA), Compositions Thereof, and Methods of UseFiled as Arrowhead Pharmaceuticals, Inc.2025-04-10Paloma Martinez-Redondo | pending |
| RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of UseA61K 47/6807, C12N 15/113, A61K 47/542, A61K 47/549, A61K 47/6849, A61P 25/28, C07K 16/2881, C12N2310/11, C12N2310/14, C12N2310/312, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-03-30Phillip Lazzara | 12551569 |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-03-30PHILLIP LAZZARA | pending |
| RNAI AGENTS FOR DUAL INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) AND PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-02-27JONATHAN VAN DYKE | pending |
| Methods For The Treatment Of ANGPTL3-Related Diseases And DisordersA61K 31/713, C12N 15/113, C12N 15/1136, A61K 47/549, A61P 9/00, A61P 3/06, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/322, C12N2310/343, C12N2310/351, C12N2320/32, C12N2320/35, C12N2310/321, C12N2310/3521, C12N2310/3533, C12N2310/332Filed as Arrowhead Pharmaceuticals, Inc.2025-02-21Javier San Martin | pending |
| RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UseA61K 31/712, C12N 15/113, A61K 47/549, A61P 43/00, A61P 37/06, A61K 31/713, A61K 47/02, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Arrowhead Pharmaceuticals, Inc.2025-02-03Jeffrey Carlson | pending |
| Compositions and Methods for Inhibition of Factor XII Gene ExpressionA61K 31/713, C12N 15/113, A61K 47/549, A61P 7/02, A61P 43/00, A61K 31/7115, A61K 31/7125, A61K 45/06, C12N2310/11, C12N2310/14Filed as Arrowhead Pharmaceuticals, Inc.2025-01-23Zhen Li | pending |
| RNAI AGENTS FOR INHIBITING EXPRESSION OF ANDROGEN RECEPTOR (AR), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-01-23CHRISTINE ESAU | pending |
| ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOFA61K 47/6807, C07K 16/2881, A61K 47/6849, A61K2039/505, C07K2317/24, C07K2317/55, C07K2317/92, C12N 15/1138, C12N2310/14, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/332, C12N2310/3513, C12N2310/3521, C12N2310/3533Filed as Arrowhead Pharmaceuticals, Inc.2025-01-23Agnieszka Glebocka | 12527877 |
| IMPROVED LINKERS AND METHODS FOR THE SYNTHESIS OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY CONJUGATESFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-01-23MATTHEW FOWLER-WATTERS | pending |
| ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOFFiled as ARROWHEAD PHARMACEUTICALS, INC.2025-01-23AGNIESZKA GLEBOCKA | pending |
| RNAi Agents for Inhibiting Expression of Huntingtin (HTT), Compositions Thereof, and Methods of UseFiled as Arrowhead Pharmaceuticals, Inc.2025-01-08Christine Esau | pending |
| METHODS AND REAGENTS FOR IMPROVED OLIGONUCLEOTIDE SYNTHESISFiled as ARROWHEAD PHARMACEUTICALS, INC.2024-12-19AGNIESZKA GLEBOCKA | pending |
| RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of UseC12N 15/111, C12N 15/113, C12N 15/1137, C07F 9/24, C07H 1/00, C07H 19/10, C07H 21/00, C07H 23/00, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/332, C12N2310/343, C12N2310/344, C12N2310/346, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/35, C12Y 207/1103Filed as Arrowhead Pharmaceuticals, Inc.2024-12-19Michelle Ngai | 12442002 |
| RNAi AGENTS FOR INHIBITING EXPRESSION OF ACTIVIN RECEPTOR-LIKE KINASE 7 (ALK7), COMPOSITIONS THEREOF, AND METHODS OF USEFiled as ARROWHEAD PHARMACEUTICALS, INC.2024-12-19MICHELLE NGAI | pending |
| LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CNS TISSUEA61K 47/542, C12N 15/113, C12N 15/1137, C07C2603/94, C07C2603/40, C07C2601/04, C07C2602/38, C07C2602/50, C07C2601/14, C07C2602/24, A61K 47/548, A61P 25/28, A61K 31/713, C07C 69/587, C07C 69/675, C07C 69/732, C07C 69/753, C07C 205/42, C07C 233/52, C07C 235/14, C07C 235/60, C07C 237/22, C07D 207/46, C07D 223/06, C07D 243/08, C07D 311/72, C07D 471/10, C07D 495/04, C07F 9/2408, C07F 9/6552, C07F 9/65586, C07H 1/00, C07H 15/04, C07H 19/04, C07H 21/00, C07J 9/005, C07J 41/0055, C12N 15/1138, C12N2310/14, C12N2310/314, C12N2310/315, C12N2310/317, C12N2310/321, C12N2310/322, C12N2310/351, C12N2310/3515, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Arrowhead Pharmaceuticals, Inc.2024-12-13Xiaokai Li | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ARWR
Company overviewEverything on ARWR in one place, with the price.SEC filingsWhat ARWR's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ARWR's own officers and directors buy and sell.Who owns itEvery manager reporting a position in ARWR.Funds holding itWhich funds and ETFs hold ARWR, and how big a bet.